Armistice Capital, LLC Establishes 5.27% Passive Stake in Travere Therapeutics, Inc. (TVTX)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G regarding their holdings in Travere Therapeutics, Inc. (TVTX). The filing reveals that as of March 31, 2026, the reporting persons beneficially own 4,897,417 shares of common stock, representing a 5.27% ownership stake in the company. This position marks a new passive holding for the investment manager, as the previous reported ownership was zero. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Under the terms of their investment management agreement, Armistice Capital exercises shared voting and dispositive power over these securities. The filing was made under Rule 13d-1(b), indicating that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Travere Therapeutics is a biopharmaceutical company based in San Diego, California.